Due to the severe adverse effects that can accompany conventional therapies for Crohn's disease, the search for natural complementary therapies has increased dramatically in recent years. Indole-3carbinol (BC), a constituent of cruciferous vegetables, possesses anti-inflammatory properties; however, its effects on intestinal inflammation have yet to be evaluated. To test the hypothesis that BC dampens intestinal inflammation, C57Bl/6 mice were treated with BC and exposed to 2,4,6-trinitrobenzenesulfonic acid (TNBS) to induce colitis. Several parameters of disease severity and inflammation were subsequently evaluated. I3C dampened the disease severity, as indicated by decreased body weight loss and decreased severity of clinical signs. Interestingly, this effect was observed in female but not male mice, which displayed a trend towards exacerbated colitis. Differential effects were observed in the profiles of cytokine production, as the production of pro-inflammatory cytokines was increased in males. The sexspecific effect of BC in TNBS-induced colitis is a novel finding and warrants further investigation since this is a common dietary compound and is also available commercially.
The desire to identify natural products to treat and prevent various diseases has increased dramatically in recent years due to the decreased satisfaction with conventional therapeutics. One compound of interest is indole-3-carbinol (BC), a prevalent constituent of cruciferous vegetables including broccoli, brussel sprouts, and cabbage. BC is primarily recognized for its potent anti-cancer properties since it has the unique ability to eliminate tumor cells while being protective in normal cells. Specifically, BC has been reported to inhibit the proliferation of estrogensensitive breast cancer cells, induce apoptosis of melanoma cells, alter cell survival of prostate cancer cells, and generate adverse effects on other tumor cells (1) (2) (3) (4) . Activities contributing the observed effects of BC include decreased proliferation, increased apoptosis, and decreased metastasis (reviewed in (5». Importantly, no immediate or long-term severe adverse effects have been documented following human consumption in several cancer clinical trials (6-9) thereby emphasizing its usefulness as a therapeutic agent.
Several molecular targets have been identified for BC and its metabolites, such as the primary acid condensation product diindolylmethane (DIM). BC and DIM can bind several cytosolic receptors and alter several important signaling pathways including the aryl hydrocarbon receptor (AhR), estrogen receptor (ER), androgen receptor (AR), and nuclear factor-kappa B (NF-KB) (6) (7) (8) (9) (10) . A complex signaling cascade is likely induced following BC exposure due to crosstalk between these pathways including physical interaction of the ligand-bound AhR with NF-KB (10, 11) and the ER (12) (13) (14) .
While BC has been primarily investigated for its anti-cancer properties, there has been increased interest in evaluating its immunomodulatory properties. It has been documented that BC can suppresses inflammation in vitro and in vivo in part by inhibiting NF-KB activation and decreasing production of inflammatory mediators (15) (16) (17) (18) . Therefore, the potential exists for this compound to be effective in reducing the severity ofchronic inflammatory diseases including Crohn's disease and ulcerative colitis, which are inflammatory bowel diseases. In fact, the BC acid condensation product DIM suppressed disease severity of dextran sodium sulfate (DSS)-induced colitis, which is an animal model of ulcerative colitis (19) . However, the potential beneficial effects of its parent compound, BC, on intestinal inflammation have yet to be investigated.
In this study we assessed the potential of BC to suppress inflammation in a murine model of Crohn's disease.
We hypothesized that BC would exert anti-inflammatory effects in the 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis. Our results demonstrate for the first time that BC exerts sex-specific effects in TNBS colitis, as it ameliorates disease severity and inflammation in female, but not male, mice. BC clearly has potential to be a useful therapeutic for intestinal inflammation; however, future studies are necessary to further define the sex-specific effects of this compound in the gut.
MATERIALS AND METHODS

Laboratory animals
Six to eight week old male and female C57Bl/6 mice, originally obtained from The Jackson Laboratories (Bar Harbor, ME), were bred and maintained in the animal research facility at the University of Montana. All mice were housed under specific pathogen-free conditions and maintained on 12 h dark/light cycles. Throughout each experiment animals were individually caged, and standard laboratory food and water were provided ad libitum. All protocols for the use of animals were approved by the University of Montana Institutional Animal Care and Use Committee and adhered to the current NIH guidelines for animal usage.
Chemicals
Indole-3-carbinol (BC) at~96'1'0 purity (as determined by HPLC) was obtained from Sigma-Aldrich (St. Louis, MO), and suspended in peanut oil, which was used as a vehicle control for gavages, at 10 mg/ml. The purity and stability ofl3C was verified in house via NMR prior to use in our study. 2,4,6-trinitrobenzenesulfonic acid (TNBS) was also obtained from Sigma-Aldrich and dissolved in acetone/olive oil for pre-sensitization or 40% ethanol for enema administration.
Colitis induction
As described in Fig. I , mice were gavaged daily starting on day -8 relative to the TNBS enema and ending on day -I with 100 mg BC per kg body weight (~200-250 ul total volume) or a comparable volume of peanut oil vehicle control prior to pre-sensitization and colitis induction. Presensitization on day -7 included an application of 150 ul 5% TNBS in a 4: 1 acetone:olive oil solution between the shoulder blades such that mice were not orally exposed to TNBS. Sham control mice that were gavaged with vehicle control and pre-sensitized with TNBS were harvested on day O. Colitis was then induced via an enema containing TNBS on day 0, as previously described (18) . Body weight loss and the severity of clinical symptoms (overall body condition, stool consistency, and dehydration state via a skin pinch test) was monitored daily and scored as previously described in detail (20) . Briefly, each parameter was individually scored on a scale of 0-3 then combined to determine the total disease activity index. On day 5, mice were euthanized via CO 2 asphyxiation followed by cervical dislocation.
Colon processing and histology
Colons were excised from each mouse and washed with PBS to remove debris. For histological analysis, a I cm section from the distal colon was fixed in 2% paraformaldehyde, processed in the Shandon Citadel 2000 Automated Tissue Processor (Thermo Fisher Scientific, Waltham, MA) with vacuum unit, embedded using the Shandon Histocentre 2 Embedding unit, sectioned at 7 urn using the Thermo Shandon Finesse 325 microtome, and stained with hematoxylin and eosin (H&E) in the Shandon Veristain 24-4 Slide Stainer. Colons were assessed microscopically by a blinded individual to determine the severity of inflammation based on an established scoring table (16) . Briefly, colon damage was based on a combination of the severity of inflammatory cell infiltration into the tissue and the severity of tissue lesions. Both parameters were based on scales of 0-3 then combined for a total possible score of 6. Slides were imaged using the Nikon E800 Microscope with Cambridge Research Instrumentation, Inc. and Nuance camera software version 1.62 at lOX magnification. The remaining colon was divided into two sections for cell isolation and homogenization in lysis buffer from which the supernatants were analyzed for cytokine production, as described below.
Cytokine assays
Supernatants from homogenized colon tissue were examined for the levels of IL-I~, IL-6, IL-lO, IL-12, IL-17, and IFN-y via enzyme-linked immunosorbent assay (ELISA). Samples were analyzed according to the manufacturer's instructions using mouse cytokine-specific BD OptEIA ELISA kits (BD Biosciences, San Diego, CA) or R&D ELISA kits (Minneapolis, MN).
qRT-PCR
RNA was isolated from colon tissue with Trizol reagent (Invitrogen, Carlsbad, CA, USA) and subjected to RNA clean-up using the Total RNA Kit with optional DNase treatment (Omega Bio-Tek, Norcross, GA, USA) according to the manufacturers' instructions. First strand cDNA synthesis was performed using qScript cDNA Supermix (Quanta Biosciences, Gaithersburg, MD, USA). Resulting cDNA was subjected to qRT-PCR using commercially obtained primers (SABiosciences, Frederick, MD or Integrated DNA Technology, Coralville, lA, USA) including aryl hydrocarbon receptor (AHR), aldehyde dehydrogenase family I, subfamily Al (ALDHIAI), aldehyde dehydrogenase family I, subfamily A2 (ALDHIA2), estrogen receptor alpha (ESRI), estrogen receptor beta (ESR2), indoleamine-2,3-dioxygenase I (IDO I), indoleamine-2,3-dioxygenase 2 (ID02), interleukin-6 (IL-6), interleukin-IO (IL-lO), interleukin-I?A (IL-I 7A), interleukin-17F (IL-17F), interleukin-22 (IL-22), transforming growth factor-beta I (TGF-~I), transforming growth factor-beta 2 (TGF-~2), and transforming growth factor-beta 3 (TGF-~3). Reactions were performed with PerfeCTa SYBR Green Supermix (Quanta Biosciences) on an Agilent Technologies Stratagene Mx3005P QPCR System (Santa Clara, CA, USA).
Flow cytometry
Lamina propria mononuclear cells from colonic tissue and cells from the mesenteric lymph nodes (MLN s) were isolated and evaluated for expression of accessory molecules by flow cytometry, as previously described . Briefly, after cells were washed with PAB (l % bovine serum albumin and 0.1% sodum azide in PBS), they were blocked with Fe block (BioLegend, San Diego, CA) to eliminate nonspecific staining. Subsequently, cells were stained for 10 min using optimal concentrations of fluorochromeconjugated monoclonal antibodies. Antibodies used in these experiments included CD4-PE (GK1.5), CD25-PerCP/Cy5.5 (PC61), CDllc-APC (HL3), MHC2-FITC (M5/114.15.2), CD103-Pacific Blue (2E7), and their corresponding isotype controls, all of which were purchased from BioLegend or BD Biosciences (San Jose, CA, USA). Two hundred thousand events were collected using a BD FACSAria flow cytometer and analyzed using FACSDiva (Version 6.1.2, BD Biosciences, San Jose, CA) and FlowJo (Version 8.7.1, TreeStar, Inc., Ashland, OR) software programs. Experimental design. The TNBS model of colitis was utilized in these studies for its usefulness in testing new therapeutics and its similarity to human mucosal inflammatory responses. Animals were gavaged daily with 100 mg/kg I3C, peripherally pre-sensitized with 5% TNBS, intrarectally injected with 2.5 mg TNBS, and subsequently harvested on day 5 for evaluation.
Treatment
Statistics
All statistical analyses were performed using GraphPad Prism 4.0a for Macintosh (GraphPad Software, San Diego, CA). Student's t-test was used to compare vehicle-treated groups and BC-treated groups while 2-way analysis of variance (ANOYA) with Bonferroni 's post-hoc test was used to compare multip le groups. Yalues p:SO.05 were determined to be significant.
RESULTS
Severity of TNBS-induced colitis is reduced with I3C treatment in females but not males
BC is a prevalent dietary compound with antiinflammatory properties so its potential to decrease inflammation in a murine model of colitis was evaluated. This compound has been used extensively in clinical trials with no serious long-term adverse effects reported. Therefore, the dose used in this study is comparable to a dose in humans taking BC supplements (21) . In order to assess the potential for B C to amelio rate colitis, key indicators that mark the onset of Crohn 's disease, including significant body weight loss, loose stools and dehydration, and colon length were evaluated first using the design described in Fig. 1 . Female mice treated with BC did not lose as much weight and recovered more rapidly than vehicle-treated mice ( Fig. 2A) . The clinical severity, as determined by the overall body condition, stool consistency, and dehydration state, was also significantly less severe in female BCtreated mice. In addition, colon lengths on day 5 post-TNBS enema were significantly greater in female mice treated with BC when compared to the vehicle controls (BC, 7.2±O.3em vs vehicle , 6.2±O.2 cm;p = 0.02). Conversely, when compared to vehicletreated mice, male mice treated with BC lost weight, regained that weight more slowly, experienced a trend towards more severe clinical signs ( Figure 2B ), and did not have any significant differences in colon lengths (BC, 7.HO.l em vs vehicle, 6.8±0.3 em; p =0.17).
A. Females
Inflammation and tissue damage in the colon decreases following treatment with 13C in females
Since intestinal inflammation associated with Crohn's disease is transmural in nature, inflammatory cell infiltration and tissue lesions were evaluated in the colon. Relative to the sham controls (that did not receive the TNBS enema), TNBS-treated mice displayed significant histological damage on day 5 post-enema. However, in line with the observed clinical signs (as described above), female BCtreated mice experienced significantly decreased inflammation in the colon when compared to vehicle-treated mice (Fig. 3A) . Conversely, a trend towards increased colonic damage was observed in male BC-treated mice relative to the vehicle-treated controls (Fig. 3B ).
13C exerts differential effects on cytokine production in colonic tissue of TNBS-exposed mice
Colitis is associated with significant production of pro-inflammatory cytokines. To better understand how BC may alter the onset of Crohn's disease, cytokine production in colonic tissue was measured. In BC-treated female mice, the levels of the inflammatory cytokine IFN-y decreased from 337 pg/ml to 174 pg/ml (Fig. 4) . Production of the anti-inflammatory cytokine IL-10 increased from 591 pg/ml to 680 pg/ml, but this was not statistically significant. It should be noted that IL-10 was significantly increased in one of the three experiments while just a trend towards increased IL-10 was observed in the other experiments. BC did not significantly alter the production of the proinflammatory cytokines TNF-a, IL-1~, IL-6, IL-12, IL-17 or IL-22 in female mice. In BC-treated male mice, IL-1~and IL-6 were both increased from 332 pg/ml to 817 pg/ml and from 66 pg/ml to 154 pg/ml, respectively. IFN-y levels decreased from 296 pg/ml to 167 pg/ml. As with female mice, BC did not alter the production ofTNF-a, IL-12, IL-17 or IL-22.
Differential regulation ofgene expression by 13C in TNBS-induced colitis
Since exposure to many dietary chemicals leads to the induction of regulatory genes (such as ALDH, IDO, and TGF-~) that correlates to decreased colitis, gene expression in the colons of mice was evaluated in vehicle-and BC-treated mice five days after the TNBS enema. Interestingly, BC-treated female mice downregulated IL-17A expression by 3.5fold (relative to vehicle control-treated mice) while male mice treated with BC upregu1ated IL-17A expression by 8.1-fold (Table I) . A similar trend was observed with IL-6 expression with decreased levels in females and increased levels in males treated with BC. Conversely, BC-treated female mice upregulated TGF-j33 by 6.7-fold while male mice downregulated TGF-j31 by 2.2-fold. There was also a trend of increased expression of ALDHlA2 in females while significantly decreased levels were observed in male mice. Notably, a trend existed for increased IL-10 expression for both female and male mice. Since BC can interact with several receptors to elicit its effects, the changes in AHR and ESR gene expression were also evaluated. Expression levels ofAHR, ESR 1, and ESR2 were unchanged in both female and male mice on day 5, post-enema.
Alterations in gut cell populations were not observed five days after TNBS enema
T cells and dendritic cells (DCs) are particularly important for maintaining homeostasis in the intestinal immune system. Therefore, cells were isolated from the colon tissue and the mesenteric lymph nodes (MLNs) and evaluated for phenotypic changes that could indicate the presence ofregulatory cells following exposure to Be. Five days after administration of the TNBS enema, no significant changes in T cells or DCs were observed (Table 11) .
DISCUSSION
The cruciferous vegetable constituent BC is a potent anti-cancer agent, but its effects on inflammatory responses, especially in the gut, are not well documented. Since BC and its primary metabolite DIM recently have been shown to produce anti-inflammatory and immunoregulatory effects in vitro (16) (17) (18) 22) , these compounds have the potential to elicit protective effects in diseases characterized by chronic inflammation. The current conventional medicines for Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract, can be accompanied by severe adverse effects so many patients have turned towards natural and complementary therapies as part of their treatment regimens. Consequently, we evaluated the potential of BC to decrease the severity of Crohn's disease using a murine model of colitis.
To characterize the effects of BC on colitis, we evaluated the hallmark signs of disease onset: significant body weight loss, clinical severity, damage to colonic tissue, and inflammatory mediator production. BC suppressed body weight loss, shortening of the colon and the severity of clinical signs, but this effect was surprisingly only observed in female mice while male mice displayed a trend to a more severe disease phenotype. Furthermore, inflammatory cell infiltration and tissue lesions were decreased in the colons of female, but not male, mice. The acid condensation product DIM has been reported to ameliorate the effects of DSS-induced colitis in terms of clinical signs and histological scoring of the gut tissue (19) . Using the prototypical AhR ligand TCDD, our laboratory recently reported that TCDD dampened disease severity in TNBSinduced colitis (20) . Because BC (and DIM) can bind to the AhR with reasonably high-affinity relative to TCDD, our results support the hypothesis that the protective effects of BC on gut inflammation in the TNBS-induced colitis model are via activation ofthe AhR signaling pathway. Future studies to specifically test this hypothesis should lead to a substantially greater understanding of the mechanisms underlying the effects ofI3C in the gut. Colitis induction is characterized by an increased production of inflammatory mediators. Thus, an important aspect of potential therapeutics would be to decrease the production of these damaging mediators. Interestingly the profile of cytokines produced in the gut was quite surprising. In our current study, we observed in female mice either significantly decreased levels of pro-inflammatory cytokines (IL-17A) or trends to that effect (IL-6), whereas several of these inflammatory mediators (IL-l/3, IL-6, IL-17A) were significantly elevated in male mice exposed to TNBS. Interestingly, DIM was reported to inhibit the expression of several inflammatory mediators including nitric oxide, PGE 2 , as well the pro-inflammatory cytokines TNF-a, IL-6, and IFN-y in the colons of DSStreated colitic mice (19) . Furthermore, NF-KB p65 activation was significantly decreased in the colonic tissue ofDIM-treated mice relative to control-treated mice. Although similarities exist between these two IBD studies, they also differ in the strain of mice used (C57Bl/6 vs Balb/c), the type of IBD induced (Crohn's disease vs. ulcerative colitis) and the form of BC utilized (BC vs DIM). Moreover, the study by Kim et al. failed to report the gender of mice used in their experiments, or if any gender differences existed following treatment of DSS-induced IBD.
More recently, our laboratory has shown that TCDD treatment of both female and male mice exposed to TNBS leads to decreased production of pro-inflammatory cytokines including TNF-a, IL-6, IL-12 and IFN-y (20) . Furthermore, TCDD treatment resulted in significant increases in the expression of AHRR, CYP1AI, and IDa 1 but decreases in IL17A and ID02 in the colons of mice after enema delivery. On the other hand, BC decreased IL17A expression (3.5-fold) in females but increased its expression (8. l-fold) in male mice suggesting that this cytokine may be contributing towards increased inflammation in TNBS-treated mice. Interestingly, a similar trend was observed for protein levels ofIL-17 in the colons of mice on day 5 post-enema. Because IL-17 plays a critical role in the development of TNBS-induced colitis in mice (23) , BC may represent a promising therapeutic for IBD based on its potential to disrupt this pro-inflammatory cytokine. Another effect ofI3C in female mice was an increase (6.7-fold) in levels ofTGF-/33 mRNA whereas TGF-/3l expression was decreased (2.2-fold) in male mice treated with Be. TGF-/3 is an important cytokine for the regulation of gut homeostasis and induced inflammatory responses in this mucosal compartment (24) (25) (26) . In our study, an effect of increased TGF-/3 expression combined with decreased IL-6 production may result in the decreased levels ofIL-l 7A and subsequently reduced gut inflammation that we observed in female mice. Conversely, decreased TGF-/3 expression combined with increased IL-61evels may underlie the significant increase in IL-17A that was observed in male mice, an effect that could enhance their inflammatory response to TNBS in the colon. Future studies aimed at modulating the IL-17 signaling pathway may help define the divergent gender-specific effects of BC in TNBS-exposed mice. Additionally, investigation of additional ligands for the AhR such as 2-( I'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) would be of particular interest to explore for its potential to alter the development or severity of IBD because it has recently been reported to disrupt other immune-mediated diseases such as EAE (a murine model of multiple sclerosis) and oral tolerance in the gut (27) (28) (29) (30) (31) .
Importantly, BC, unlike TCDD, did not have lasting effects on AHRR or CYP1A 1 gene expression in the colon tissue of TNBS-treated mice (data not shown), likely because BC is much less stable than TCDD and thus prone to relatively rapid excretion. It also suggests that AhR activation alone may not be the primary mechanism underlying the suppression of colitis in females. These differences instead suggest that different mechanisms of action are responsible for mediating the effects of the dietary AhR ligands, TCDD and Be. Since BC possesses anti-estrogenic properties (5, 32) , the estrogen receptor (ER) may also play a role, especially since the AhR and the ER have been demonstrated to physically interact, an outcome that has negative effects on the estrogen signaling pathway (12) (13) (14) . Although we did not observe changes in ER expression five days after colitis induction, additional studies assessing the role of the ER in mediating the effects of BC in TNBS colitis are clearly warranted.
Despite an underwhelming effect on proinflammatory cytokines in female mice on day 5 post-TNBS enema in our study, BC may be acting on several important immune cells in the gut to ameliorate colitis. Dendritic cells (DCs) play important role in maintaining intestinal immune homeostasis. In a recent report from our laboratory, we demonstrated that bone marrow-derived DCs grown in the presence of BC and cultured with antigen-specific naive CD4+ T cells induced Foxp.l" regulatory T cells (Tregs) (18) . Therefore, it is possible that DCs increased Tregs in the gut consequently leading to the decreased gut inflammation observed in BCexposed mice. This would be consistent with what we observed in TNBS-treated mice exposed to TCDD (20) . Although we did not observe any significant alterations in cell populations on day 5 post-enema, it is plausible that the functions of DCs and T cells in the mesenteric lymph nodes and colon tissue were altered earlier in the inflammatory response as we previously reported with TCDD. Thus, there may be direct and/or indirect effects of BC on T cells in the gut, and this possibility should be further evaluated.
Taken together, our results demonstrate the novel finding that BC imparts sex-specific effects in the TNBS colitis model. Since these findings could have significant implications for Crohn's disease patients consuming increased amounts of cruciferous vegetables and/or BC dietary supplements, additional studies are warranted to define the specific mechanisms responsible for the divergent effects on colonic inflammation induced by BC.
